Martin Pålsson

The Institut Pasteur is a private non-profit foundation which contributes to the prevention and treatment of disease, through research, education, and public health activities. The firm was founded in 1887, and is based in Paris.

Van Herk Investments BV (VHI) is the private equity investment arm of the Van Herk Groep BV, based in Rotterdam. The parent firm was established in the 1950s as a family business with a focus on real estate investments. VHI invests in listed and unlisted firms across diverse sectors primarily in The Netherlands.

Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland.

Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands.

Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France.

Van Herk Groep BV provides investment services to the real estate, energy, and life science sectors. The company was founded by Aat van Herk and is headquartered in Rotterdam, the Netherlands.

Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom.

Apposite Capital LLP (Apposite Capital) is a private equity arm of Mizuho Financial Group, Inc. founded in 2016 by David Porter. The firm is headquartered in London, United Kingdom.

Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Immunexpress Pty Ltd. engages in creating molecular diagnostics for sepsis. The company was founded by Roslyn Brandon, Mervyn Rees Thomas and Richard Bruce Brandon and in 2006 and is headquartered in Toowong, Australia.

Uni Targeting Research AS is a holding company that provides the biopharmaceutical industry with tools and services for mammalian cell-line based development procedures and production processes. It offers upstream solutions to reduce complementary deoxyribonucleic acid and mammalian cell-line based timelines and increase protein production yields. Its technology enables both enhanced synthesis/secretion of naturally secreted proteins, and secretion of intracellular proteins. Its services include vector improvement, tailor-made vectors, and tool proteins. The company was founded by Ian Fraser Pryme, John E. Hesketh, Albert Tauler, and Beate Stern in 2001 and is headquartered in Bergen, Norway.

Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark.

Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA.

APIM Therapeutics AS develops and commercializes novel anti-cancer therapies. It offers a physiological intervention point allowing the potentiation of the action of clinical drugs across multiple cancer indications. The company focuses on the development and commercialization of novel anti-cancer therapies potentiating chemo-therapy induced responses in cancer cells. The company was founded by Marit Otterlei in 2009 and is headquartered in Trondheim, Norway.

Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark.

Pcovery ApS develops drugs for treatment of invasive fungal infections. It discovers a new class of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The company was founded by Morten J. Buch-Pedersen, Michael Broberg Palmgren, Claus Olesen and Poul Nissen in 2009 and is headquartered in Copenhagen, Denmark.

Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom.

Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.

SkylineDx BV develops molecular diagnostic tests for blood cancers. The firm focuses on the development and commercialization of gene signature-based diagnostic tests, which assist healthcare professionals in making personalized treatment decisions for individual patients. Its products include MMprofiler and AMLprofiler. The company was founded by Dharminder S. Chahal and Bob Löwenberg in 2005 and is headquartered in Rotterdam, the Netherlands.

Glionova AB develops cancer treatment drugs. The firm is a drug discovery and development company. It offers GLN-1001 product. The company was founded by Lars G. J. Hammarström and Patrik Ernfors in 2014 and is headquartered in Stockholm, Sweden.

Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland.

ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom.

IO Biotech ApS operates as a clinical stage biotech company. It develops immunotherapy for cancer by targeting a mechanism used by tumour cells to evade immune responses. The company was founded by Mai-Britt Zocca, Mads Hald Andersen, Inge Marie Svane, Anders Ljungqvist and Per Thor Straten and is headquartered in Copenhagen, Denmark.

Zelluna Immunotherapy AS engages in research and development on biotechnology. The company is headquartered in Oslo, Norway.

de Hoben GmbH is a private company that was founded in 2017 and engages in the buying and selling of land, buildings, and apartments. The company is based in Dusseldorf, Germany.

Affinicon ApS operates as a biotechnology company. It develops combinatory drugs for treatment of diseases such as inflammation, infections, and certain forms of cancer. The firm exploits a novel platform technology for targeted delivery of known drugs to macrophages. The company was founded by Niels Jonas Heilskov Graversen on July 4, 2013 and is headquartered in Aarhus, Denmark.